Gracell Biotechnologies Inc. (NASDAQ: GRCL)
|
|
---|---|
Pricing data not available |
Open: | $ n/a | Volume: | n/a | |
---|---|---|---|---|
High: | $ n/a | Yield(%) | n/a | |
Low: | $ n/a | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | n/a | |
EPS ($) | n/a | Shares Out: | n/a |
% Price Change (last 4 weeks): | 0.00 |
---|---|
% Price Change (last 13 weeks): | 0.00 |
% Price Change (last 26 weeks): | 1.49 |
% Price Change (last 52 weeks): | 167.28 |
% Price Change (year to date): | 2.09 |
Return on Equity (%): | -37.23 |
---|---|
Return on Assets (%): | -32.14 |
Return on Invested Capital (%): | -38.19 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Gracell Biotechnologies, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of discovering and developing cell therapies to resolve industry challenges and fulfill unmet medical needs in the treatment of cancer. The company was founded by Wei Cao in May 2017 and is headquartered in Suzhou, China.
|
Gracell Biotechnologies Inc.
Biobay & Suzhou Industrial Park 218 Sangtian Street Building 12, Block B, Phase II Suzhou SH 215123 Phone: 86.512.6262.6701 Fax: n/a http://www.gracellbio.com |
Earnings (1year) ($): | -1.02 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 2.92 |
Cash Flow ($): | -1.20 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 0.79 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 6.78 |
---|---|
Current Ratio (x): | 6.78 |
LT Debt/Equity (x): | 3.85 |
Total Debt/Equity (x): | 13.30 |